Could a common diabetes drug protect arteries in type 1 diabetes?

NCT ID NCT04583462

Ongoing Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether metformin, a drug used for type 2 diabetes, can slow the buildup of calcium in leg arteries of people with type 1 diabetes. 230 adults will take either metformin or a placebo for two years. The goal is to see if metformin reduces artery hardening, which can lead to heart problems and amputations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Metformin
What this could lead to: If it works, this could point toward a way to reduce dangerous artery hardening in people with type 1 diabetes, potentially lowering heart and limb risks.
What could go wrong: This is a phase 3 trial, but metformin is already widely used for type 2 diabetes. It may not work for this specific complication, and side effects like stomach upset are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERIPHERAL ARTERIAL CALCIFICATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PERIPHERAL ARTERIAL CALCIFICATION TYPE 1 DIABETES

Contacts and locations

Locations

Pitié Salpêtrière Hospital, AP-HP, Diabetology department

Paris, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.